The Use of Ferrokinetics in the Study of Experimental Anemia

by Eun Woo Lee,* James J. Kocsis,† and Robert Snyder†

Erythropoietic cells in bone marrow are vulnerable to cytotoxic substances. There are three types of erythroid precursors: cells that can take up Fe but do not proliferate (reticulocytes), those that can take up Fe and proliferate (normoblasts and pronormoblasts), and those cells that do not take up Fe but can proliferate and differentiate into the erythroid cell line (ERC and stem cells). Each of these erythroid precursors requires a certain time before they emerge into the peripheral blood as mature red blood cells. By applying our understanding of ferrokinetics associated with erythropoiesis, it was possible to estimate a cytotoxic effect of chemicals on proliferating erythroid precursors (pronormoblasts) in mice by measuring 24-hr \( ^{59} \)Fe uptake in red blood cells 48 hr after treatment with chemicals. The effect of chemicals on pluripotent hemopoietic stem cells in mice was also estimated by measuring 24-hr \( ^{59} \)Fe uptake 72 hr after treatment with chemicals. The validity of experimental schemes was tested using cytarabine, methotrexate, vinblastine, cyclophosphamide, and busulfan, which are known to act against specific cell types. Effects on pluripotent hemopoietic stem cells were tested with or without activation of stem cells in G0 into cell cycle. Applications of the \( ^{59} \)Fe uptake method in the study of (1) benzene toxicity and (2) effect of pentobarbital on the toxic action of hydroxyurea and cytarabine are described. Proper application of the ferrokinetic characteristics of erythropoietic cells enables the establishment of a methodology which can be used to evaluate potential toxic effects of chemicals on erythroid precursor cells and pluripotent hemopoietic stem cells.

Introduction

Bone marrow, a dynamic system which produces blood cells, is vulnerable to cytotoxic agents. The erythropoietic system retains several characteristics that allow for a rather precise experimental evaluation of the system: the response of early erythroid precursor cells to erythropoietin, the capability of erythroid cells to synthesize hemoglobin, and the existence of a histochemical marker for reticulocytes. By using ferrokinetic features and other developmental characteristics of cells involved in erythropoiesis, it was possible to measure the relative size of a cellular pool of different erythroid precursor cells affected by chemical agents. We believe such a methodology can be used for an assessment of hazard caused by cytotoxic agents on erythropoietic cells including hemopoietic stem cells.

This presentation will discuss: ferrokinetics involved in erythropoiesis, rationale in the application of ferrokinetics for evaluating chemically induced erythropoietic toxicity, an experimental scheme and test for the rationale, and application of the \( ^{59} \)Fe uptake method for the assessment of potential erythropoietic toxins.
Ferrokinetics Involved in Erythropoiesis

The earliest erythropoietic cell that can be recognized morphologically is pronormoblast. This cell is derived from the erythropoietin response cell (ERC), and the ERC is derived from pluripotent hemopoietic stem cells. There is evidence that pluripotent hemopoietic stem cells are the progeny of more primitive hemopoietic stem cells (1-4). Pronormoblasts differentiate and mature sequentially into normoblasts, reticulocytes, and erythrocytes (Fig. 1). All cells from the ERC to the normoblast are in cell cycle and thus proliferate (5, 6) while reticulocytes and erythrocytes do not. In rodents, most pluripotent hemopoietic stem cells (90-95%) are not in cycle; i.e., they are in Go state (7, 8), but they can be activated into cell-cycle upon specific physiological stimuli (9-11). Under normal conditions, only 5-10% of stem cells are in cell cycle, and these constitute the ERC pool. The cells from pronormoblasts to reticulocytes can synthesize hemoglobin (6). Therefore, they can take up $^{59}$Fe, but stem cells and ERC do not take up Fe because they do not make hemoglobin. Thus, from the ferrokinetic point of view, the cells involved in erythropoiesis can be classified into three categories: cells that take up Fe but do not proliferate (reticulocytes), cells that take up Fe and proliferate (normoblasts and pronormoblasts), and finally, cells that do not take up Fe but can proliferate and differentiate into the erythroid cell line, i.e., ERC and stem cells.

Rationale for the Application of Ferrokinetics for Evaluating Chemically Induced Erythropoietic Toxicity

The time required for each of the erythrocyte precursor cells to mature and to be released into the circulating blood has been determined in mice. The turnover time of reticulocytes and the generation times of both pronormoblasts and normoblasts are about 24 hr (12-15). In these studies, it was decided that the size of the reticulocyte pool would be used as a measure of the effects of chemicals on each of the earlier cell types by administering $^{59}$Fe, which rapidly disappears from the circulation, and sampling the peripheral blood for $^{59}$Fe uptake 24 hr later, a time at which the label in the blood represents incorporation of the iron into hemoglobin during the period when maturation and release of the cells into the circulation occurs. Therefore, the cytotoxic effect of an agent on normoblasts in mice can be evaluated by giving $^{59}$Fe when the affected erythroid precursors mature to the stage of reticulocytes, i.e., 24 hr after treatment with the agent and by measuring the amount of $^{59}$Fe in the circulating red blood cells 24 hr after giving $^{59}$Fe, a time interval which allows the bone marrow reticulocytes to be released into the blood (Fig. 1). The time when $^{59}$Fe is injected as opposed to the time when the blood sample is taken is the time when the size of the reticulocyte compartment is measured in

![Figure 1. Developmental sequences of cells involved in erythropoiesis experimental scheme for determining the effect of agent on each cellular compartment: (a) proliferating cells; (b) nonproliferating cells but can be activated to proliferating cells; (c) nonproliferating mature cells.](image-url)
this scheme because $^{59}$Fe is taken up by reticulocytes at the time of $^{59}$Fe injection. By the same token, the effect of agents that damage the pronormoblasts can be reflected by the 24 hr $^{59}$Fe uptake value which is measured 48 hr after treatment with the agent.

It has also been shown that it takes 24 hr for the ERC to differentiate into pronormoblasts (12). Regarding stem cells, there is no information on the time required for the cells to differentiate into ERC. However, our experimental data, which will be discussed shortly, suggest that stem cells differentiate into ERC immediately upon physiological stimulus. Thus, we suggest that the effect of agents that inhibit pluripotent hemopoietic stem cells and ERC can be seen when $^{59}$Fe is given 72 hr after treatment with the agent and 24 hr $^{59}$Fe uptake is measured.

**Experimental Scheme and Tests**

In order to test the validity of the rationale, three types of cytotoxic agents, for which the mechanism of action is known, were chosen. Methotrexate and cytarabine are S-phase specific cytotoxic agents and can kill only proliferating cells (16-22), while cyclophosphamide and busulfan are cell-cycle stage nonspecific agents and can kill both proliferating and nonproliferating cells such as hemopoietic stem cells (23-26). Vinblastine produces both metaphase arrest of mitosis and some damage to hemopoietic stem cells (23, 27). The effect of these cytotoxic agents on each compartment of erythroid precursors were determined by the 24-hr $^{59}$Fe uptake measured 24, 48, 72, and 96 hr after injection of a single dose of the agent.

Cytarabine and methotrexate lowered $^{59}$Fe uptake 24 and 48 hr after treatment with the agent, respectively, as expected, but at 72 and 96 hr $^{59}$Fe uptake was increased over control values (Fig. 2). An interpretation of the overshoot may be that the ERC pool was immediately replaced by an excessive number of pluripotent stem cells as a compensatory mechanism when cytarabine and methotrexate killed the proliferating ERC, pronormoblasts, and normoblasts (28). An alternative explanation could be that more cell divisions might be inserted in the pronormoblast and normoblast compartments by a shortening of the intermitotic time (29). However, this latter process cannot be the reason for the overshoot because $^{59}$Fe is given after the cells of the maturing compartments have already been released into the blood. Thus, the overshoot indicates that the ERC pool was immediately replaced by an excessive number of stem cells.

Otherwise, a reduction of the $^{59}$Fe uptake value should have been observed when it was measured 72 hr after treatment with methotrexate or cytarabine because they kill ERC. Cyclophosphamide and busulfan reduced $^{59}$Fe uptake at all times, as expected, confirming that the action of cell-cycle stage nonspecific agents on nonproliferating stem cells can be measured by the $^{59}$Fe uptake method. Vinblastine reduced the $^{59}$Fe uptake at both 24 and 48 hr and also less severely at 72 hr, as expected. Here again, the $^{59}$Fe uptake at 96 hr after vinblastine exceeded the control value, suggesting that the damage on erythropoietic system activated G0 stem cells into cell cycle.

The fact that the 24-hr $^{59}$Fe uptake measured 72 hr after treatment with cytotoxic agents reflects the effect of the agents on the stem cell compartment is further supported by the following experiments. Three doses of 50 mg/kg of cytarabine were given every 2 hr over a 4-hr period and 24-hr $^{59}$Fe uptake was measured 72 hr after the last dose of cytarabine. Under these conditions, the $^{59}$Fe uptake was not affected (Table 1). However, when a primary dose of 50 mg/kg of cytarabine was given 12 hr prior to the same series of three doses of 50 mg/kg at 2-hr intervals and 24-hr $^{59}$Fe uptake was measured 72 hr after the last dose, a significant reduction of $^{59}$Fe uptake by 65% was produced. On the basis of the spleen colony forming unit assay (CFU-S) (30), it has been shown that pluripotent stem cells in the G0 state can be induced to synthesize DNA and divide by cytarabine (10, 31).

![Figure 2](image-url)  
**Figure 2.** Twenty-four hour $^{59}$Fe uptake in mice measured at different time intervals following a single IP dose of cytarabine (150 mg/kg), methotrexate (20 mg/kg), vinblastine (2 mg/kg), cyclophosphamide (200 mg/kg), and a single sc dose of busulfan (320 mg/kg). Values represent the mean of 10 mice per group and were significantly different in all cases except those at 24 hr after busulfan, 72 hr after methotrexate, and 96 hr after cytarabine; 72 hr after cytarabine and also at 96 hr after methotrexate and vinblastine the significance of the differences was $p < 0.05$ whereas in all other cases the differences were $p < 0.001$.  

June 1981
Thus, the reduction of $^{59}$Fe uptake following a primary dose of cytarabine, but no reduction without the primary dose, further supports the notion that the 24-hr $^{59}$Fe uptake measured 72 hr after treatment with cytotoxic agent reflects the effects of agents on nonproliferating pluripotent stem cells.

**Application of the $^{59}$Fe Uptake Method for the Assessment of Potential Erythropoietic Toxins**

**Erythropoietic Toxicity of Benzene Measured by the $^{59}$Fe Uptake Method**

Effect of a single subcutaneous dose of benzene (88, 440, and 2200 mg/kg as a 50% benzene-olive oil solution) in mice was evaluated by parameters such as erythrocyte $^{59}$Fe uptake, total leukocyte counts and hematocrits 24 hr after benzene administration. To determine the $^{59}$Fe uptake, mice were given $^{59}$Fe (0.5 μCi, 20-40 ng of iron) as ferrous citrate 24 hr after benzene treatment and bled 24 hr later. Unless specified, $^{59}$Fe was injected IP throughout the study. Blood (0.2 ml) from each mouse was counted in a scintillation well counter and the percentage of the $^{59}$Fe taken up into erythrocytes was calculated, assuming a blood volume of 6% of the body weight. Statistical significance was determined by means of Student's $t$ test. Experimental results in Table 2 indicate that the $^{59}$Fe uptake measurement is a more sensitive method than total leukocyte counts and hematocrits for evaluating bone marrow activity.

The stage of erythroid cell development sensitive to benzene was evaluated using the $^{59}$Fe uptake method. Mice were given single doses of benzene sc and its effect on $^{59}$Fe uptake was evaluated after five specific time intervals (Fig. 3). No suppression was found after 1 and 12 hr and also 72 hr, whereas dose-dependent inhibition of the $^{59}$Fe uptake was observed 24 hr and 48 hr after treatment with 440 or 2200 mg/kg dose. Thus, the data can be interpreted to suggest that (1) benzene did not interfere with an incorporation of iron into heme, (2) benzene interfered with proliferation of normoblasts and pronormoblasts, and (3) benzene did not damage hemopoietic stem cells which were in the G0 state at the time of benzene injection.

![Figure 3](image_url)

**Table 1. Effect of dose schedules of cytarabine on $^{59}$Fe uptake in mice.**

| Total dose of cytarabine, mg/kg | Schedule of administration | 24 hr $^{59}$Fe uptake measured 72 hr after cytarabine (mean ± SD), %a |
|-------------------------------|---------------------------|---------------------------------------------------------------------|
| Saline control                | Three times, 0.2 ml every 2 hr | 22.6 ± 7.6 (8)                                                      |
| 150                           | Three times, 50 mg/kg every 2 hr | 23.2 ± 8.0 (10)                                                   |
| 300                           | Single injection           | 29.0 ± 10.6 (9)                                                   |
| 200                           | Initial dose, 50 mg/kg 12 hr prior to three successive doses of 50 mg/kg every 2 hr | 7.8 ± 6.1b (6)                                                   |

*aNumber of animals given in parentheses.
bSignificantly lower than control values ($p < 0.001$).
Table 2. Effect of a single dose of benzene on rbc $^{59}$Fe utilization, total leukocyte, and hematocrit in mice.

| Benzene dose, mg/kg | 24-hr $^{59}$Fe utilization, % | Total leukocyte/mm$^3$ | Hematocrit Mean ± SD$^a$ |
|---------------------|--------------------------------|------------------------|-------------------------|
|                     | Mean ± SD$^a$ | CV$^b$ | Mean ± SD$^a$ | CV$^b$ | Mean ± SD$^a$ |
| Olive oil control   | 24.3 ± 4.8 (14)$^b$ | 19.8 | 5991 ± 2492 (16) | 42 | 46 ± 3.8 (16) |
| 88                  | 24.7 ± 6.1 (19) | 28.7 | 5540 ± 2519 (15) | 45 | 45 ± 6.7 (15) |
| 440                 | 17.8 ± 3.7$^c$ (19) | 20.8 | 4661 ± 1833 (14) | 35 | 47 ± 2.6 (14) |
| 2200                | 12.1 ± 4.5$^c$ (15) | 37.2 | 4585 ± 1551 (17) | 34 | 46 ± 3.9 (17) |

$^a$Number of animals given in parentheses.
$^b$CV = coefficient of variation (standard deviation/mean × 100).
$^c$Significantly lower than the value of control group ($p < 0.001$).

caused by a toxic metabolite of benzene. The implication of benzene metabolites in benzene toxicity is further described in review articles (33, 34).

The liver is generally accepted as the major site of benzene metabolism. Thus, the role of the liver in producing benzene-induced bone marrow depression was investigated using partially hepatectomized rats. Partial hepatectomy (35) resulted in removal of 75 ± 8% (16 rats) of the liver. Sham operations were performed by making a middle incision reaching 1-1.5 cm posteriorly from the xiphoid process of the sternum, exposing the median and left lateral lobes of the liver, and then closing the area with no liver excision. A single dose of benzene (2200 mg/kg) was injected SC 8 hr after surgery. Generally, labeled $[^3]$Hbenzene (approximately 80,000 dpm/µmole) was administered to determine benzene metabolites in urine (36 hr cumulative urinary radioactivity). Total radioactivity in urine was reported as benzene equivalents in µmoles. To determine radioiron utilization, $^{59}$Fe (1.0 µCi per rat) was injected IP 48 hr after benzene administration and sample blood was collected 24 hours after $^{59}$Fe administration for analysis. The percentage of $^{59}$Fe incorporated into erythrocytes was calculated assuming a blood volume of 6% of the body weight.

Sham-operated and partially hepatectomized control rats showed no difference in $^{59}$Fe uptake, indicating that partial hepatectomy itself had no effect on $^{59}$Fe uptake. Benzene reduced $^{59}$Fe uptake to about half of the control values in sham-operated animals (Table 4). No reduction in $^{59}$Fe uptake, however, was observed in the benzene-treated partially hepatectomized rats, showing that partial hepatectomy protected the rat against benzene-induced bone marrow depression. On the other hand, partial hepatectomy markedly reduced benzene metabolism, confirming the requirement for the production of a metabolite which mediates benzene toxicity.

Table 3. Effects of toluene on benzene metabolism and on $^{59}$Fe uptake in the mouse.

| Treatment | $[^3]$H Benzene metabolism/24 hr, % of administered dose (mean ± SD)$^a$ | 24 hr $^{59}$Fe Utilization, % of administered dose (mean ± SD)$^{a,b}$ |
|-----------|------------------------------------------------------------------|---------------------------------------------------------------|
| Control   | 24.2 ± 4.7 (27)                                                  | 23.3 ± 4.6 (25)                                              |
| Toluene (1720 mg/kg) | 35.8 ± 1.1 (2)$^d$                                                    | 15.7 ± 4.8$^b$ (21)                                        |
| Benzene (440 mg/kg) | 10.9 ± 7.5 (2)$^d$                                                 | 22.0 ± 5.9$^b$ (28)                                        |
| Benzene and toluene | 18.5 ± 6.2 (22)                                                   | 15.8 ± 5.5 (19)                                              |
| Control   | 22.6 ± 5.7 (17)                                                  | 4.9 ± 3.4$^d$ (19)                                         |
| Toluene (1720 mg/kg) | 9.9 ± 3.9 (17)                                                   | 9.9 ± 4.5$^d$ (17)                                         |

$^a$Number of mice given in parentheses.
$^{b,c}$Fe was injected 48 hr after benzene or toluene administration.
$^d$Significantly different from both control and toluene groups ($p < 0.05$).
$^e$Significantly different from group receiving benzene alone ($p < 0.05$).
Table 4. Effect of partial hepatectomy on erythrocyte $^{59}$Fe utilization and urinary metabolites of benzene in rats after a single injection of benzene.

|                  | Sham operation$^a$ | Partial hepatectomy$^a$ |
|------------------|-------------------|-------------------------|
|                  | $^{59}$Fe utilization, %$^b$ | $^{59}$Fe utilization, %$^b$ |
| Control (olive oil) | 31.6 ± 13.3 (9)$^b$ | 29.1 ± 6.5 (10) |
| Benzene (2200 mg/kg, SC) | 15.4 ± 6.7 (10)$^c$ | 36.4 ± 16.2 (10) |
| Urinary metabolites, benzene equivalent, μmol$^d$ | 132.2 ± 52.2 (4) | 40.5 ± 19.8 (5)$^c$ |
| $[^3]$H Benzene (2200 mg/kg, SC) | | |

$^a$Mean ± SD: the number of animals is given in parentheses.
$^b$Based on administered dose: 24 hr $^{59}$Fe uptake was measured 48 hr after benzene administration.
$^c$Significantly different from control sham-operated rats ($p < 0.01$) and from benzene-treated partially hepatectomized rats ($p < 0.01$).
$^d$Measured as 36 hr cumulative urinary radioactivity.

Table 5. Effect of pentobarbital on the action of multiple doses of cytarabine on the $^{59}$Fe uptake measured 48 hr after treatment.

| Groups                  | 24 hr $^{59}$Fe uptake at various doses of cytarabine (mean ± SD), %$^a$ |
|------------------------|------------------------------------------------------------------------|
|                        | 25 mg/kg × 3$^b$       | 20 mg/kg × 3$^b$       | 100 mg/kg × 3$^b$   |
| Control, saline        | 20.5 ± 8.9 (16)        | 19.8 ± 3.6 (16)        | 21.1 ± 3.9 (19)     |
| Pentobarbital$^c$      | 20.5 ± 5.2 (18)        | 20.7 ± 5.2 (17)        | 20.7 ± 5.8 (13)     |
| Cytarabine             | 13.2 ± 4.7 (16)        | 6.6 ± 4.0 (17)         | 3.1 ± 1.5 (18)      |
| Pentobarbital$^d$ + cytarabine | 16.1 ± 5.4 (22)   | 11.8 ± 4.0$^c$ (21)  | 6.9 ± 2.8$^c$ (17)  |

$^a$Number of mice given in parentheses.
$^b$Three doses were given at 2 hr intervals. The 24 hr $^{59}$Fe uptake was measured 48 hr after the last dose of cytarabine.
$^c$Two or three successive doses of 60 mg/kg to maintain anesthesia for 6 hr.
$^d$Pentobarbital (60 mg/kg) was given 1 hr prior to cytarabine and anesthesia was maintained for 6 hr by 1 or 2 additional dose(s) of pentobarbital.
$^e$Significantly higher than the value of cytarabine treated group ($p < 0.001$).

(36-38) and cytotoxic agents (39), the effect of pentobarbital on the cytotoxic action of cytarabine and hydroxyurea to erythrocytic progenitors (pronormoblasts) and hemopoietic stem cells in cell cycle were investigated using the $^{59}$Fe uptake method.

Data in Table 5 show that pentobarbital alone had no effect on pronormoblasts, while cytarabine given in three doses of 25, 50, or 100 mg/kg every 2 hr produced dose-dependent damage on pronormoblasts. When pentobarbital was given 1 hr prior to cytarabine and anesthesia was maintained until 1 hr following the last dose of cytarabine, the inhibition of $^{59}$Fe uptake by pentobarbital was significantly reduced at 50 and 100 mg/kg × 3, indicating that pentobarbital alleviated the toxicity of cytarabine on proliferating erythroid cells. Similar results were also obtained with hydroxyurea (Table 6).

Experimental results of pentobarbital action on the proliferating hemopoietic stem cells challenged with hydroxyurea is shown in Table 7. Here also, pentobarbital alone had no effect on the stem cells.

Table 6. Effect of pentobarbital on the action of multiple doses of hydroxyurea on the $^{59}$Fe uptake measured 48 hr after treatment.

| Group                  | 24 hr $^{59}$Fe uptake (mean ± SD), %$^{a,b}$ |
|------------------------|---------------------------------------------|
| Control, saline        | 40.6 ± 9.0 (15)                             |
| Pentobarbital$^c$      | 37.9 ± 9.5 (13)                             |
| Hydroxyurea$^d$        |                                              |
| 167 mg/kg × 3          | 12.6 ± 3.9 (12)                             |
| 333 mg/kg × 3          | 6.5 ± 2.8 (10)                              |
| Pentobarbital + hydroxyurea$^e$ | 23.3 ± 7.3$^f$ (16)   |
| 167 mg/kg × 3          | 17.5 ± 4.7$^f$ (15)                         |
| 333 mg/kg × 3          |                                              |

$^{a,b}$ was given IV.
$^b$Number of mice given in parentheses.
$^c$Two or three successive doses of 60 mg/kg to maintain anesthesia for 6 hr.
$^d$Three doses were given at 2 hr intervals. The $^{59}$Fe uptake was measured 48 hr after the last dose of cytarabine.
$^e$Pentobarbital (60 mg/kg) was given 30 min prior to hydroxyurea and anesthesia was maintained for 6 hr by 1 or 2 additional dose(s) of pentobarbital.
$^f$Significantly higher than the value of hydroxyurea treated group ($p < 0.001$).

Environmental Health Perspectives
Table 7. Effect of pentobarbital on the action of hydroxyurea on the $^{59}$Fe uptake measured 72 hr after treatment.

| Group                      | Schedule of administration                                      | $^{59}$Fe uptake (mean ± SD) | $^{59}$Fe uptake | $^{59}$Fe uptake |
|----------------------------|-----------------------------------------------------------------|------------------------------|------------------|------------------|
| Control                    | Saline, 0.1 ml three times at 2 hr intervals                    | 34.1 ± 6.4 (13)              | 34.1 ± 6.4       | 34.1 ± 6.4       |
| Pentobarbital              | Two or three doses of 60 mg/kg to keep anesthesia for 6 hr      | 38.5 ± 9.5 (9)               | 38.5 ± 9.5       | 38.5 ± 9.5       |
| Hydroxyurea Schedule A     | Three successive doses of 500 mg/kg at 2 hr intervals           | 35.9 ± 7.7 (9)               | 35.9 ± 7.7       | 35.9 ± 7.7       |
| Schedule B                 | Initial dose (2000 mg/kg) 12 hr prior to three doses of 500 mg/kg every 2 hr | 11.5 ± 5.2$^c$ (10)          | 11.5 ± 5.2       | 11.5 ± 5.2       |
| Pentobarbital + hydroxyurea| Hydroxyurea given by schedule B and pentobarbital given 30 min prior to 3 doses of hydroxyurea for 6 hr | 22.8 ± 5.4$^d$ (10)          | 22.8 ± 5.4       | 22.8 ± 5.4       |

$^{59}$Fe was given IV
$^a$Number of mice given in parentheses.
$^b$Significantly lower than control values ($p < 0.001$).
$^c$Significantly higher than the value of hydroxyurea treated (schedule B) group ($p < 0.001$).

Table 8. Effect of pentobarbital on the action of cytarabine on the $^{59}$Fe uptake measured 72 hr after treatment.

| Groups                      | Schedule of administration                                      | Mean ± SD, % | % of control |
|-----------------------------|-----------------------------------------------------------------|--------------|--------------|
| Control                     | Saline, 0.1 ml three times at 2 hr intervals                    | 23.2 ± 6.8 (10) | 100.0        |
| Pentobarbital               | Two or three successive doses of 60 mg/kg to maintain anesthesia for 6 hr | 23.4 ± 4.4 (10) | 100.9        |
| Cytarabine Schedule A       | Three successive doses of 150 mg/kg every 2 hr                  | 22.4 ± 7.2 (8) | 96.6         |
| Schedule B                  | Initial dose (150 mg/kg) 12 hr prior to three successive doses of 100 mg/kg every 2 hr | 3.9 ± 3.8$^b$ (10) | 16.8         |
| Pentobarbital + cytarabine  | Cytarabine given by schedule B and pentobarbital given 1 hr prior to three successive doses 15.4 ± 3.3$^b$ (10) | 66.4         |

$^a$Number of mice given in parentheses.
$^b$Pentobarbital anesthesia was maintained for 6 hr by two or three successive doses of 60 mg/kg.
$^c$Significantly lower than control values ($p < 0.001$).
$^d$Significantly higher than the value of cytarabine treated group ($p < 0.001$).

Hydroxyurea, which is also a S-phase specific agent (16, 40, 41), did not affect the $^{59}$Fe uptake when the stem cells are in $G_0$. However, when an initial dose of hydroxyurea (2000 mg/kg) was given 12 hr prior to three successive doses of hydroxyurea (500 mg/kg every 2 hr, schedule A), the $^{59}$Fe uptake value was reduced to 32% of the hydroxyurea treated group given schedule A alone. Several groups of investigators have independently shown that an initial dose of hydroxyurea activated $G_0$ stem cells into cell cycle on the basis of the CFU-S assay (11, 42, 43). Thus, the present data confirms that the S-phase specific agent, hydroxyurea, can only kill the proliferating cells whether they are stem cells or pronormoblasts but it can not kill cells in the $G_0$ state such as resting hemopoietic stem cells. When pentobarbital is given 30 min prior to the three successive doses of hydroxyurea following an activation of $G_0$ stem cells, the $^{59}$Fe uptake value was increased twofold. This protective effect of pentobarbital on proliferating stem cells was also observed when they were insulted with cytarabine (Table 8). The mechanism by which pentobarbital protects proliferating hemopoietic cells from cytotoxic agents remains to be seen. In summary, the proper application of ferrokinetics and other developmental characteristics of erythropoietic cells enables the establishment of a methodology which can be used to estimate the potential toxic effect of chemicals on erythropoietic cells and pluripotent hemopoietic stem cells.

REFERENCES

1. Abramson, S., Miller, R. G., and Phillips, R. A. The identification in adult bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J. Exp. Med. 145: 1567 (1977).
2. Tretin, J., Wolf, N., and Cheng, U. Antibody production by mice repopulated with limited numbers of clones of lymphoid cells. J. Immunol. 98: 1326 (1967).

3. Curry, J. L., and Tretin, J. Hemopoeitic spleen colony studies. I. Growth and differentiation. Dev. Biol. 15: 395 (1967).

4. Hodgson, G. S., and Bradley, T. R. Properties of haemopoietic stem cells surviving 5-flurourouracil treatment: evidence for pre-CFU-S cell? Nature 291: 361 (1970).

5. Morse, B. S., Rencercia, N. J., and Stohman, F. Jr. Relationship of erythropoietin effectiveness to the generative cycle of erythrocyt precursor cell. Blood 35: 761 (1970).

6. Payne, B. J., Lewis, H. B., Murchinson, T. E., and Hart, E. A., Hematology of laboratory animals. In: Handbook of Laboratory Science, Vol. III, E. C. Melby, Jr., and N. H. Altman, Eds., CRC Press, Cleveland, Ohio, 1976, pp. 383-461.

7. Lajtha, L. G., Pozi, L. V., Schofield, R., and Fox, M. Kinetic Properties of Haemopoietic Stem Cells. Cell Tissue Kinet. 2: 39 (1969).

8. Lord, B. I., Lajtha, L. G., and Gidal, J. Measurement of the kinetic status of bone marrow precursor cells: three cautionary tales. Cell Tissue Kinet. 7: 507 (1974).

9. Metcalf, D., and Moore, M. A. S. Haemopoietic Cells, American Elsevier, New York, 1971, pp. 70-109.

10. Blackett, N. M. Cell cycle characteristics of haemopoietic stem cells. In: Stem Cells of Renewing Cell Populations, A. B. Cairnie, P. K. Lala, and D. G. Osmond, Eds., Academic Press, New York, 1976, pp. 157-164.

11. Vassort, F., Winterholer, M., Frindel, E., and Tubina, M. Kinetic parameters of bone marrow stem cells using in vivo suicide by tritiated thymidine and hydroxyurea. Blood 41: 789 (1973).

12. Filmanowicz, E., and Gurney, C. W. Studies on erythropoiesis. XVI. Response to a single dose of erythropoietin in polycytemic mouse. J. Lab. Clin. Med. 57: 65 (1961).

13. Altman, K. I., and Russel, E. S. Heme synthesis in normal and genetically anemic mice. J. Cell Comp. Physiol. 64: 293 (1964).

14. Nakao, K., Takahn, F., Fujoka, S., and Sassa, S. The effects of erythropoietin on hemopoietic organs of the polycytemic mouse. Blood 27: 537 (1966).

15. Lee, E. W., Kocsis, J., and Synder, R. Acute effect of benzene on $^{57m}$Fe incorporation into circulating erythrocytes. Toxicol. Appl. Pharmacol. 27: 431 (1974).

16. Skipper, H. E., Shabel, F. M. Jr., Mellett, L. B. Montgomery, J. A., L., L. J., and Brumnan, R. W. Implication of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. 54: 431 (1970).

17. Creasy, W. A., DeConti, R. C., and Kaplan, S. R. Biochemical studies with $^{1-}$arabinofuranosylcytosine in human leukemic leukocytes and normal bone marrow cells. Cancer Res. 28: 1074 (1968).

18. Chu, M. Y., and Fisher, G. A. Effects of cytosine arabinoside on the cell viability and uptake of deoxyxyrimidine nucleosides in L5178Y cells. Biochem. Pharmacol. 17: 741 (1968).

19. Graham, F. L., and Whitmore, G. F. The effect of $^{1-}$arabinofuranosylcytosine on the growth viability and DNA synthesis of mouse L-cells. Cancer Res. 30: 2627 (1970).

20. Werkeheiser, W. C. Specific binding of 4-amino acid analogues of folic acid reductase. J. Biol. Chem. 236: 888 (1961).

21. Blackett, N. M. Investigation of bone-marrow stem cell proliferation in normal, anemic, and irradiated rats using methotrexate and tritiated thymidine. J. Natl. Cancer Inst. 41: 909 (1968).

22. Bertino, J. R., Booth, B. A., Cashmore, A. R., Beiber, A. L., and Sartorelli, A. C. Studies on the inhibition of dihydrofolate reductase by folate antagonists. J. Biol. Chem. 239: 479 (1964).

23. van Putten, L. M., and Lelieveld, P. Factors determining cell killing by chemotherapeutic agents in vivo. I. Cyclophosphamide. Europ. J. Cancer 6: 313 (1970).

24. Bruce, W. R., Meeker, B. E., and Valeriote, F. A. Comparison of the sensitivity of normal hemopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J. Natl. Cancer Inst. 37: 233 (1966).

25. Millar, J. L., and Blackett, N. M. The effect of various cytotoxic agents on the erythroid precursors in rat bone marrow. Brit. J. Haematol. 26: 336 (1974).

26. Morley, A., and Blake, J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood 44: 49 (1974).

27. Twentyman, P. R., and Blackett, N. M. Action of cytotoxic agents on the erythroid system of the mouse. J. Natl. Cancer Inst. 44: 117 (1970).

28. Becker, A. J., McCulloch, E. A., Siminovitch, L., and Till, J. E. The effect of different demands for blood cell production on DNA synthesis by haemopoietic colony forming cells of mice. Blood 26: 296 (1965).

29. Tarbutt, R. G. Cell population kinetics of the erythroid system in the rat. The response to protracted anaemia and continuous $r$-irradiation. Brit. J. Haematol. 16: 9 (1969).

30. Till, J. E., and McCulloch, E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14: 213 (1961).

31. Necas, E., and Neuwirt, J. Proliferation rate of haemopoietic stem cells after damage by several cytostatic agents. Cell Tissue Kinet. 9: 479 (1976).

32. Ikeda, M., Ohtsui, H., and Imamura, T. In vivo suppression of benzene and styrene oxidation by co-administered tolune in rats and effects on phenobarbital. Xenobiotica 2: 101 (1972).

33. Snyder, R., and Kocsis, J. J. Current concepts of chronic benzene toxicity. Crit. Rev. Toxicol. 3: 265 (1975).

34. Snyder, R., Andrews, L. S., Lee, E. W., Witmer, C. M., Reilly, M., and Kocsis, J. J. Benzene metabolism and toxicity. In: Biological Reactive Intermediates, D. J. Jallow, J. J. Kocsis, R. Snyder, and H. Vaino, Eds., Plenum Press, New York, 1977, pp. 286-309.

35. Higgin, G. M., and Anderson, R. M. Experimental pathology of the liver: I. Restoration of the liver of the white rat following partial surgical removal. Arch. Pathol. 12: 186 (1931).

36. Keizer, H. J., and van Bekkum, D. W. Effects of various anaesthetics on stem cell survival after irradiation of mice. Intern. J. Radiat. Biol. 20: 192 (1971).

37. Keizer, J. H., and van Putten, L. M. The radioprotective action on bone marrow CFU during immobilization of mice. Radiat. Res. 66: 326 (1976).

38. Riches, A. C., Littlewood, V., and Thomas, D. B. The effects of irradiation on the haemopoietic tissues of anaesthetized mice. Acta Haematol. 50: 50 (1973).

39. Keizer, H. J., and van Putten, L. M. An increase of CFU survival in the mouse bone marrow after irradiation and chemotherapy during narcosis. Intern. J. Radiat. Biol. 25: 629 (1974).

40. Morse, B. S., Rencercia, N. J., and Stohman, F. Jr. The effect of hydroxyurea on differential marrow erythroid precursors. Proc. Soc. Exptl. Biol. Med. 130: 886 (1968).

41. Sinclair, W. K. Hydroxyurea: effects on Chinese hamster cells grown in culture. Cancer Res. 27: 297 (1967).
42. Monette, F. C., Gilis, M. J., and Cahifoux, P. Separation of proliferating CFU from G cells of murine bone marrow. Cell Tissue Kinetics 7: 443 (1974).

43. Necas, E., and Neuwirt, J. Control of haemopoietic stem cell proliferation by cells in DNA synthesis. Brit. J. Haemat. 33: 395 (1976).